MedTrace Logo

Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES)

NCT04820673 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2024-10-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the patient-reported outcomes (PROs) in terms of health-related quality of life (HRQoL) and signs of Acne Vulgaris (AV) among patients with moderate to severe non-nodular AV who are administered sarecycline (Seysara®) in real-world community practice settings in the United States (U.S). Investigator's Global Assessment (IGA) of AV and safety measures associated with use of sarecycline (Seysara®) will be assessed over the study observation period of 12 weeks. Clinicians will prescribe sarecycline (Seyara®) as per their own clinical judgment and standard practice.

Conditions

  • Acne Vulgaris

Interventions

DRUG

Sarecycline

Clinicians will prescribe the sarecycline as per their own clinical judgment and standard practice.

Sponsors & Collaborators

  • Almirall, S.A.

    lead INDUSTRY

Principal Investigators

  • Study Director · Almirall, S.A.

Eligibility

Min Age
9 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-09
Primary Completion
2022-05-04
Completion
2022-05-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04820673 on ClinicalTrials.gov